Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Pharming

Thumbnail
August 13, 2019

Novartis cast-off gives Pharming a gap-filler

Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?

Thumbnail
October 12, 2018

Cost-effectiveness doubts could hit Shire’s Takhzyro launch

A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.

Article image
Vantage logo
September 19, 2018

The other shoe drops for Pharming

A US complete response letter leaves Ruconest at the mercy of rivals like Shire.

Article image
Vantage logo
August 09, 2018

Shire dodges pricing questions as lanadelumab’s big day nears

Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?

Vantage logo
March 09, 2018

Snippet roundup: A fillip for Pfizer but Merck KGaA comes under pressure

Vantage logo
November 22, 2016

Pharming bets the house on Ruconest

Vantage logo
August 12, 2016

Snippet roundup: Lilly pill slips, Mek inhibitors reach limit, Myriad buys

Vantage logo
August 12, 2016

Interview – Pharming’s last chance lies with solo strategy

Vantage logo
August 10, 2016

A new Valeant starts to take shape, and it's still not pretty

Vantage logo
July 15, 2016

Snippet roundup: Immuno-oncology hopes for Parkinson's class, Coherus climbs

Vantage logo
February 24, 2016

The US FDA shows its teeth

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.